Health

AI ยท 251 companies ยท 438 deals tracked
251 Companies
438 Deals Tracked
AI Sector

Health Companies

Uk Research And Innovation Uk Research And Innovation ๐Ÿ‡ฌ๐Ÿ‡ง Apella Apella ๐Ÿ‡บ๐Ÿ‡ธ Synthpop Synthpop ๐Ÿ‡บ๐Ÿ‡ธ Prana Labs Prana Labs ๐Ÿ‡จ๐Ÿ‡ฆ Emerald ๐Ÿ‡ฌ๐Ÿ‡ง Qura Qura ๐Ÿ‡ฎ๐Ÿ‡น You(th) You(th) ๐ŸŒ Health Universe Health Universe ๐Ÿ‡บ๐Ÿ‡ธ Nokia ๐ŸŒ Neuropacs Neuropacs ๐Ÿ‡บ๐Ÿ‡ธ

Latest Deals in Health

$80M
Proxima, an AI-native biotech company based in New York, has secured an oversubscribed $80 million seed round led by DCVC, with participation from notable investors including NVIDIA's NVentures and Roivant. The company focuses on developing proximity therapeutics that enhance disease-fighting events by manipulating protein interactions, addressing a significant gap in drug discovery. Proxima's innovative platform combines structural data with AI to create new medicines for previously untreatable targets, with several co-developed programs set to enter clinical trials this year.
Investors: DCVC, NVIDIA's NVentures, Roivant
Health Jan 14, 2026
$80M
Proxima, an AI-native biotech company based in New York, has secured an oversubscribed $80 million seed round led by DCVC, with participation from notable investors including Nvidiaโ€™s NVentures and Roivant. The company focuses on developing proximity therapeutics that enhance disease-fighting mechanisms by manipulating protein interactions. Proxima aims to address the challenge of limited structural data in drug discovery, leveraging its Neolink technology and Neo AI model to create new therapies for previously untreatable targets. The funding will support its mission to make these innovative treatments widely accessible.
Investors: DCVC, Nvidiaโ€™s NVentures, Roivant
Health Jan 14, 2026
$80M
Proxima, an AI-native biotech company based in New York, has secured an oversubscribed $80 million seed round led by DCVC, with participation from notable investors including NVIDIAโ€™s NVentures and Roivant. The company focuses on developing proximity therapeutics that enhance disease-fighting mechanisms by manipulating protein interactions. Proxima's innovative platform combines structural data with AI to create new therapeutic options for previously untreatable conditions. The funding will support its mission to make these therapies more accessible.
Investors: DCVC, NVIDIAโ€™s NVentures, Roivant
Health Jan 14, 2026
$80M
Proxima, an AI-native biotech company focused on drug discovery tools for proximity-based medicines, has raised an oversubscribed $80 million seed round. The financing was led by DCVC, with participation from notable investors including NVIDIAโ€™s venture capital arm, Roivant, and others. This funding will help Proxima advance its development of proximity therapeutics, addressing significant challenges in drug discovery.
Investors: DCVC, NVIDIA, Roivant
Health Jan 14, 2026
Modella AI, a Boston-based leader in artificial intelligence for life sciences, has been acquired by AstraZeneca to enhance their oncology research and development. The acquisition aims to integrate Modella AI's multi-modal foundation models and AI agents, addressing the complexities of oncology drug development. Financial details were not disclosed, but the collaboration is expected to accelerate clinical development and improve patient outcomes.
Health Jan 14, 2026
$11.1M
Risa Labs has secured $11.1 million in Series A funding to enhance its AI-driven operating system for oncology, aimed at improving workflows in cancer clinics, health systems, specialty pharmacies, and infusion networks across the United States.
Health Jan 13, 2026
$80M
Proxima, a New York City-based AI-native biotech company, raised $80 million in seed funding to develop AI-driven drug discovery for proximity therapeutics. The funding round was led by DCVC, with participation from notable investors including nVentures, Braidwell, Roivant, and others. This investment aims to enhance drug discovery processes using advanced AI technologies.
Investors: DCVC, nVentures, Braidwell, Roivant
Health Jan 13, 2026
$11.1M
Risa Labs, a Palo Alto, California-based provider of an AI operating system for oncology, closed an $11.1 million Series A funding round. The round was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon via his VentureForGood investment firm. The company plans to use the funds to accelerate its growth.
Investors: Cencora Ventures, Optum Ventures, Oncology Ventures, Z21 Ventures, John Simon
Health Jan 13, 2026
$100M
OpenAI has acquired Torch, a small health records startup, in a deal valued at approximately $100 million in equity. The acquisition aims to enhance OpenAI's capabilities in health-related applications, with Torch's four-person team joining OpenAI, indicating a focus on talent acquisition rather than a traditional buyout.
Health Jan 13, 2026
$6.5M
AI4Eyes Medical Technologies has raised C$6.5 million to develop and commercialize AI-powered eye care solutions. This funding includes C$3.7 million from existing investors and C$2.8 million in non-dilutive funding. The capital will enhance the company's financial position and support regulatory approval activities in Canada and the United States, as well as product development for clinical use. The funding aims to facilitate strategic partnerships and commercialization readiness in global markets.
Health Jan 13, 2026
$3.125M
Outsee, a Cambridge, England-based developer of an AI-based predictive genomics approach to target discovery, raised ยฃ2.5 million in seed funding. The round was led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 independent angel investors. The company plans to use the funds to advance its therapeutic targets through experimental validation.
Investors: Ahren Innovation Capital, Kadmos Capital, Panacea, Empirical Ventures, 26 independent angel investors
Health Jan 13, 2026
$5.7M
Avenue Biosciences, a Finnish protein engineering company, has raised $5.7 million in a seed extension round co-led by Balnord and Tesi, with additional participation from Voima Ventures, Inventure, University of Helsinki, and Dimerent. The funding aims to enhance protein biogenesis efficiency in therapeutic protein production, addressing challenges in manufacturing complex proteins. The total funding since 2024 now stands at $8.7 million, leveraging research from the University of Helsinki.
Investors: Balnord, Tesi, Voima Ventures, Inventure, University of Helsinki, Dimerent
Health Jan 13, 2026
$33.5M
Juvena Therapeutics has raised $33.5 million in a Series B financing round to enhance its clinical-stage regenerative biologics programs and expand its AI-enabled discovery capabilities. The funding aims to address challenges in regenerative medicine.
Health Jan 12, 2026
$3.125M
Outsee, an AI-enabled genomics and drug discovery company, has secured ยฃ2.5 million in seed funding. This funding will support a collaborative drug discovery program with O2h Discovery focused on Outsee's lead drug target candidate.
Health Jan 12, 2026
$5M
Allos AI has secured $5 million in seed financing to develop its innovative 'glass-box' causal AI platform aimed at reformulating complex generic drugs. This funding addresses the need for lower-risk methods to enhance the delivery and tolerance of established medications over extended use, appealing to developers and manufacturers in the pharmaceutical industry.
Health Jan 12, 2026
$6.5M
ai4eyes medical technologies, based in Montreal, Canada, has closed a $3.7 million CAD internal financing round alongside $2.8 million CAD in non-dilutive funding, totaling $6.5 million CAD. This funding will enhance the company's balance sheet and support its development of AI-powered eye care solutions.
Health Jan 12, 2026
Enablecomp has acquired health resources optimization, inc. (h/roi) to enhance its revenue cycle management capabilities. This acquisition aims to address the challenges of clinical denials and revenue recovery for hospitals facing margin pressures. Enablecomp serves over 1,000 hospitals and recovers $3 billion annually, leveraging AI-driven technology to improve financial performance. Key investors include Greenberg Advisors, who served as financial advisors in the deal.
Investors: Greenberg Advisors
Health Jan 12, 2026
$5M
Allos, an Oxford, UK-based company utilizing causal AI for clinical outcomes, raised $5 million in seed funding. The round was led by Oxford Science Enterprises with participation from Habico Invest, the family office of Danish pharmaceutical group Orifarm, and the University of California accelerator Berkeley SkyDeck. The funds will support the company's expansion.
Investors: Oxford Science Enterprises, Habico Invest, University of California accelerator Berkeley SkyDeck
Health Jan 12, 2026
$43M
Viecure has raised $43 million to enhance its software platform aimed at assisting community oncology clinics in providing precision-medicine care more efficiently. This funding will support the expansion of AI-powered cancer care solutions in these practices.
Health Jan 12, 2026
$50M
Cambridge-based biotech firm bit.bio has raised $50 million in funding, led by M&G Investments. The funding will accelerate product development, enhance accessibility, and expand into the toxicology market. Bit.bio's technology provides reliable human cells for research, reducing reliance on animal testing and improving pre-clinical research accuracy. CEO Przemek Obloj emphasized the importance of this investment in driving innovation in drug development.
Investors: M&G Investments
Health Jan 12, 2026